Details for Patent: RE48839
✉ Email this page to a colleague
Which drugs does patent RE48839 protect, and when does it expire?
Patent RE48839 protects CAPLYTA and is included in one NDA.
This patent has twenty-one patent family members in nine countries.
Summary for Patent: RE48839
Title: | Methods and compositions for sleep disorders and other disorders |
Abstract: | Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. |
Inventor(s): | Mates; Sharon (New York, NY), Fienberg; Allen (New York, NY), Wennogle; Lawrence (Hillsborough, NJ) |
Assignee: | Intra-Cellular Therapies, Inc (New York, NY) |
Application Number: | 16/784,112 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent RE48839
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-002 | Apr 22, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF BIPOLAR DEPRESSION | ⤷ Try a Trial | ||||
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-002 | Apr 22, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF SCHIZOPHRENIA | ⤷ Try a Trial | ||||
Intra-cellular | CAPLYTA | lumateperone tosylate | CAPSULE;ORAL | 209500-003 | Apr 22, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF SCHIZOPHRENIA | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: RE48839
PCT Information | |||
PCT Filed | May 27, 2009 | PCT Application Number: | PCT/US2009/003261 |
PCT Publication Date: | December 03, 2009 | PCT Publication Number: | WO2009/145900 |
International Family Members for US Patent RE48839
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2009251816 | ⤷ Try a Trial | |||
Australia | 2015218433 | ⤷ Try a Trial | |||
Canada | 2725342 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |